Navigation Links
ofatumumab in Medical News

Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma

Summary: Genmab has Initiated a Phase II Study of Ofatumumab in Relapsed Diffuse Large B-Cell Lymphoma COPENHAGEN, Denmark, December 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that study centers have been initiated and are ready to enroll patients in...

Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program

Summary: Genmab and GSK Have Announced the Initiation of the Phase III Program With Ofatumumab to Treat Rheumatoid Arthritis. COPENHAGEN, Denmark, November 20 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today the initiation of the ...

GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer

...t (refractory) to previous therapies. If approved, ofatumumab would be the first anti-CD20 monoclonal antibody a...se effects.(4) "The submission of the BLA for ofatumumab brings us closer to the possibility of providing a... in these patient groups treated with single-agent ofatumumab was 58 percent for the fludarabine alemtuzumab ref...

GlaxoSmithKline's Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL

...ision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that GlaxoSmithKline's ofatumumab will become Decision Resources' proprietary clinical gold-standard treatment for relapsed/refractory chronic lymphocytic leukemia (CLL) by 2012. This ...

Genmab Announces 2008 First Half Year Results

...follows: We achieved a development milestone for ofatumumab (HuMax-CD20(R)) under the collaboration with Glaxo...evaluate a subcutaneous route of administration of ofatumumab (HuMax-CD20(R)) in rheumatoid arthritis (RA). We... results from a Phase III pivotal study evaluating ofatumumab (HuMax-CD20(R)) in two groups of patients with chr...

The Monoclonal Antibodies Drug Market for the Treatment of Cancer Will More Than Double to $16.7 Billion By 2016

...onstrained environment limits off-label use. Market sales will also be driven by the introduction of four new MAbs by 2016: Genmab/GlaxoSmithKline's ofatumumab for non-Hodgkin's lymphoma and chronic lymphocytic leukemia, Medarex/Bristol-Myers Squibb's ipilimumab for malignant myeloma, Genmab's zanolimumab for...

GlaxoSmithKline Presents Innovative Neuroscience Pipeline

...arketed therapies -- Phase II program for use of ofatumumab in multiple sclerosis announced, with trials i...r more effective and more convenient treatments. ofatumumab (HuMax-CD20), a promising monoclonal antibody, wil...ine Seretide TORCH Volibris (EU) ofatumumab (RA) (EU) Tykerb (US) Requip XL (PD) (U...
ofatumumab in Medical Technology

Recruitment Completed in Ofatumumab NHL Pivotal Study

Summary: Genmab has Completed Recruitment of Patients in the Phase III Study of Ofatumumab in Rituximab Refractory Follicular NHL COPENHAGEN, September 23 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of patients in the pivotal Phase III st...

Genmab Announces Upcoming Ofatumumab Studies

Front Line CLL, NHL and CLL Retreatment and Japanese Development Studies Planned COPENHAGEN, Denmark, August 25 /PRNewswire-FirstCall/ -- Genmab has announced plans to begin four studies of ofatumumab in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. ...

Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study

Summary: Phase III Pivotal Study of Ofatumumab in Refractory CLL Meets Primary Endpoint COPENHAGEN, July 31 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today positive top-line results from an interim analysis of ...

Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study

COPENHAGEN, Denmark, July 9 /PRNewswire-FirstCall/ -- Summary: Genmab has completed recruitment of patients in the Phase II study of ofatumumab in combination with fludarabine and cyclophosphamide to treat front line CLL. Genmab A/S (OMX: GEN) announced today it has completed recruitment of ...

Genmab Reaches Milestone in Ofatumumab Collaboration

Summary: Genmab has Reached a Milestone in its Ofatumumab Collaboration With GlaxoSmithKline COPENHAGEN, June 30 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached a development milestone for ofatumumab (HuMax-CD20(R)) under the terms of its...

Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study

COPENHAGEN, Denmark, June 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today a Phase I/II study to evaluate a subcutaneous route of administration of ofatumumab (HuMax-CD20(R)) in rheumatoid arthritis (RA) patients, stable on methotrexate will be initiated soon. The study, whic...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

...ease is refractory to fludarabine and alemtuzumab. ofatumumab is an investigational treatment. "The committee's positive vote in support of ofatumumab is a potential milestone for patients with CLL. Wh...ies. "The positive vote by ODAC confirms that ofatumumab may offer a new treatment option for patients who ...

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

... Data from a pivotal trial suggests that ofatumumab has activity in heavily pre-treated patients who h...ia (CLL). The results demonstrate the potential of ofatumumab for heavily pre-treated patients with CLL who do n...merican Society of Hematology, 6-9 December, 2008. ofatumumab is an investigational drug that has not been appro...

Genmab Announces Updates on Phase III Cancer Studies

...nterim analysis (N=132 patients) in the pivotal Phase III clinical trial of ofatumumab (HuMax-CD20(R)) in refractory chronic lymphocytic leukemia (CLL) has now re...cation in this indication is expected to be filed before the end of 2008. ofatumumab is an investigational drug being developed to treat CLL, follicular non-Hod...

GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)

...(abstract number: OPO232) from a Phase II study of ofatumumab (HuMax-CD20(R)) in patients with rheumatoid arthritis (RA). ofatumumab is being co-developed under a worldwide agreement ...f four treatment groups (300 mg, 700 mg or 1000 mg ofatumumab or placebo) and assessed based on their of Rheumat...
ofatumumab in Biological Technology

Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH

Responses Significantly Correlated to Overall Survival Summary: Three ofatumumab Abstracts Have Been Accepted for Presentation at the ASH Meeting December 6-9, 2008 COPENHAGEN, November 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that three of...

Genmab Reaches Milestone in Ofatumumab Collaboration

Summary: Genmab has Reached the Sixth Milestone in its Ofatumumab Collaboration With GSK. COPENHAGEN, Denmark, October 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the sixth milestone for ofatumumab (HuMax-CD20(R)) under the terms ...

Genmab Reaches Fifth Milestone in Ofatumumab Collaboration

Summary: Genmab Will Receive a Milestone Payment of Approximately DKK 232.7 Million From GSK for Achievement of Positive Results in the Phase III CLL Study COPENHAGEN, August 21 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the fi...

Genmab Reaches Milestones in Ofatumumab Collaboration

Summary: Genmab has Achieved Two Development Milestones in its Ofatumumab Collaboration With GlaxoSmithKline. COPENHAGEN, January 21 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the second and third development milestones for ofatumumab (HuMax-...

Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis

Summary: Genmab has Announced Details of a Planned Phase II Study of Ofatumumab to Treat Relapsing Remitting Multiple Sclerosis COPENHAGEN, Denmark, December 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today details of a planned Phase II study of ofatumumab (HuMax-CD20...

Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study

Summary: Genmab and GlaxoSmithKline Have Completed Recruitment of 66 CLL Patients Respectively to Both Study Groups in a Pivotal Study of ofatumumab COPENHAGEN, Denmark, November 28 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today recruitment of 132 patients has been completed i...

Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study

Summary: Genmab has Amended the Design of the Ofatumumab Pivotal Study in Rituximab Refractory Follicular Non-Hodgkin's lymphoma and Reduced the Number of Patients to Approximately 81 COPENHAGEN, September 27 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it ...

Genmab Announces Encouraging Preclinical Data for ofatumumab

Summary: Genmab Announces ofatumumab Appeared More Effective Than rituximab in a Pre-Clinical Study COPENHAGEN, Denmark, September 7 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that ofatumumab (HuMax-CD20(R)) appeared more effective at inducing compleme...

Genmab Announces Results for the First Nine Months of 2008

... results from a Phase III pivotal study evaluating ofatumumab (HuMax-CD20(R)) in two groups of patients with chr...nt. We completed recruitment in a second pivotal ofatumumab study in refractory non-Hodgkin's Lymphoma (NHL) p... We announced plans to begin four studies with ofatumumab this year: 1) Phase III CLL front line chlorambu...

Genmab Announces Year End 2007 Financial Results

...xpenses. Of the research and development costs, we expect to spend approximately DKK 500 million (approximately USD 98 million) on development for the ofatumumab program. Total projected revenues for 2008 are expected to be approximately DKK 1.0 billion (approximately USD 197 million), an increase of approxim...
Other Tags
(Date:3/28/2015)... 28, 2015 An article in Fortune ... could prove critical to organizations that deal with PCI ... aspect of data security, is worsening . Using ... report, every major category out of the twelve measured ... “With all the craziness that has gone on in ...
(Date:3/28/2015)... 2015 How best to treat and ... in orthopaedic medicine. While diagnostic hip injections are commonly ... pain etiology, research presented today at the American Orthopaedic ... suggests that pain relief from this diagnostic injection may ... , “Our study looked to assess if the amount ...
(Date:3/28/2015)... Andrew Hawley of Vintage Rock Posters Inc., ... posters. The Who and the Doors played together at the ... According to Hawley, “The Who toured the United States heavily ... campuses. Perhaps the most famous Who poster was a poster ... Doors on August 2, 1968 at the Singer Bowl in ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... a groundbreaking new method of sustainable health. After 18 ... walks of life, including professional UFC contenders, Dr. Jon ... system this summer. , Just some of the immediate ... of energy and vitality, increased levels of strength of ...
(Date:3/28/2015)... Paso Robles, CA (PRWEB) March 28, 2015 ... damage restoration specialists , this week released a report ... worsen the symptoms of asthma sufferers, and according to ... healthy children. , According to the Environmental Protection ... can develop asthmatic reactions. Breathing in mold may trigger ...
Breaking Medicine News(10 mins):Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3
(Date:3/12/2015)... 2015 WHEN:Tuesday, March 17, 2015 at 11:00 ... . SPEAKERS: , Frost & Sullivan Measurement & ... Biometric companies must plan for ... different markets and industries. This is especially true ... Join Frost & Sullivan,s upcoming ...
(Date:3/10/2015)... --  Tute Genomics , pioneer in affordable, accurate and ... company PrimBio Research Institute to be its ... interpretation. PrimBio, a certified Life Technologies Ampliseq ... to support the work of experts on the front ... of exome sequencing services: 1) Targeted Exome and 2) ...
(Date:3/2/2015)... , March 2, 2015 Synaptics Inc. ... of human interface solutions, today announced a new ... designed to enable rapid and secure transactions and ... for gaming is a turnkey solution providing mouse ... to quickly integrate fingerprint ID solutions into their ...
Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
Other Contents